Sign inCreate account

Report workspace tools

NCT07360080RECRUITINGanonymous

Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care

Sponsor

Source record

Sanofi

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Type 1 Diabetes (Stage 2)

Indication / condition

AI-normalized

Type 1 Diabetes

Intervention

Source record

Teplizumab

Source & freshness

Source record

NCT ID

NCT07360080

Original source

ClinicalTrials.gov

Source last updated

May 27, 2026

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07360080

Title

Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care

Sponsor

Sanofi

Status

RECRUITING

Phase

Observational

Condition raw

Type 1 Diabetes

Condition normalized

Type 1 Diabetes

Modality raw

Type 1 Diabetes

Modality normalized

monoclonal antibody

Target raw

Type 1 Diabetes (Stage 2)

Target normalized

Type 1 Diabetes (Stage 2)

Interventions

Teplizumab

Public preview

Source record

Sanofi is conducting a prospective cohort study to evaluate the long-term outcomes of teplizumab treatment in patients with Stage 2 Type 1 Diabetes. The study aims to assess the drug's effectiveness in delaying the onset of Stage 3 T1D and its impact on patients' quality of life through various patient-reported outcomes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07360080

Status

RECRUITING

Phase

Observational

Sponsor

Sanofi

Executive brief

Investment-Ready Snapshot

Sanofi is conducting a prospective cohort study to evaluate the long-term outcomes of teplizumab treatment in patients with Stage 2 Type 1 Diabetes. The study aims to assess the drug's effectiveness in delaying the onset of Stage 3 T1D and its impact on patients' quality of life through various patient-reported outcomes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 27, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07360080

Indication

Type 1 Diabetes

Modality

monoclonal antibody

Target

Type 1 Diabetes (Stage 2)

Intervention

Teplizumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.